Last updated: February 19, 2026
What is ONGLYZA and its Therapeutic Application?
ONGLYZA, with the active pharmaceutical ingredient saxagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It functions by increasing levels of incretin hormones, which are naturally occurring substances that help regulate blood glucose. Specifically, ONGLYZA enhances the body's own system to reduce elevated glucose levels in adults with type 2 diabetes mellitus. It is typically used in conjunction with diet and exercise [1].
Who are the Key Stakeholders and Manufacturers?
ONGLYZA was originally developed by Bristol Myers Squibb (BMS) and AstraZeneca. In 2014, AstraZeneca took full control of the global diabetes alliance with BMS. This alliance included ONGLYZA, as well as other diabetes medications like BYDUREON, GLYXAMBI, and XIGDUO XR [2]. As of the latest available information, AstraZeneca is the primary manufacturer and marketer of ONGLYZA.
What is the Global Market Size and Growth Trajectory for DPP-4 Inhibitors?
The global market for DPP-4 inhibitors has experienced significant growth, driven by the rising prevalence of type 2 diabetes worldwide and the drug class's efficacy and generally favorable safety profile compared to some older antidiabetic agents. Market research reports indicate a compound annual growth rate (CAGR) for the DPP-4 inhibitor market ranging between 4% and 7% over the past five years. Projections suggest continued expansion, although at a moderating pace due to increasing competition from newer drug classes and the availability of generics for some DPP-4 inhibitors.
| Year |
Estimated Market Size (USD Billion) |
Projected CAGR (2023-2028) |
| 2023 |
12.5 |
5.2% |
| 2028 |
16.2 |
- |
Source: Various market analysis reports [3, 4]
What are the Key Patent Expirations and Generic Entry Timelines for ONGLYZA?
The patent landscape for ONGLYZA has been a critical factor in its market exclusivity and subsequent revenue generation. Key patents related to the composition of matter and methods of use have expired or are nearing expiration in major markets.
- United States: The primary patents for ONGLYZA began expiring around 2023. This has opened the door for generic versions to enter the U.S. market.
- Europe: Patent expiries in key European countries also occurred in the early 2020s, leading to generic competition.
- Other Regions: Patent expiration timelines vary by country based on local patent laws and regulatory approvals.
The entry of generic saxagliptin has a direct impact on ONGLYZA's market share and pricing power. Generic manufacturers can offer the drug at a significantly lower cost, leading to price erosion for the branded product.
How have ONGLYZA's Sales Performed Over Time?
ONGLYZA achieved significant commercial success following its launch. Its sales trajectory has been influenced by factors including clinical trial data, physician adoption, marketing efforts, and competitive pressures.
| Year |
Global Net Sales (USD Billion) |
| 2015 |
1.17 |
| 2016 |
1.32 |
| 2017 |
1.38 |
| 2018 |
1.43 |
| 2019 |
1.37 |
| 2020 |
1.19 |
| 2021 |
1.01 |
| 2022 |
0.86 |
| 2023 |
0.67 |
Source: AstraZeneca Annual Reports [5, 6]
The sales figures show a peak around 2018-2019, followed by a decline. This decline is attributable to several factors, including increased competition from other DPP-4 inhibitors and newer classes of diabetes medications such as SGLT2 inhibitors and GLP-1 receptor agonists, as well as the impending or actual entry of generic saxagliptin.
What is the Competitive Landscape for ONGLYZA?
The DPP-4 inhibitor class, while effective, faces a dynamic competitive environment. ONGLYZA competes with other DPP-4 inhibitors, as well as drugs from entirely different pharmacological classes that offer alternative mechanisms of action for managing type 2 diabetes.
Direct Competitors (DPP-4 Inhibitors):
- Januvia (sitagliptin): Developed by Merck & Co., Januvia is the market leader in the DPP-4 inhibitor class and has also faced generic competition.
- Tradjenta (linagliptin): Developed by Boehringer Ingelheim and Eli Lilly and Company, Tradjenta has also seen strong market penetration.
- Nesina (alogliptin): Developed by Takeda Pharmaceutical Company.
Broader Antidiabetic Market Competition:
The most significant competitive threat to ONGLYZA and other DPP-4 inhibitors comes from newer drug classes that have demonstrated cardiovascular and renal benefits, which are increasingly important considerations in diabetes management.
- SGLT2 Inhibitors: Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana). These drugs have shown significant benefits in reducing cardiovascular events and slowing kidney disease progression.
- GLP-1 Receptor Agonists: Liraglutide (Victoza), Semaglutide (Ozempic, Rybelsus), Dulaglutide (Trulicity). These agents also offer cardiovascular benefits and often lead to significant weight loss, a desirable outcome for many type 2 diabetes patients.
The clinical profile of ONGLYZA, while effective for glycemic control, does not offer the same level of demonstrated cardiovascular or renal protective benefits as many of the newer SGLT2 inhibitors and GLP-1 receptor agonists, leading to a shift in prescribing patterns towards these classes.
What are the Regulatory Considerations and Market Access Challenges?
Regulatory approval for ONGLYZA was obtained from major health authorities including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). However, market access and prescribing are influenced by pharmacoeconomic evaluations and formulary decisions by payers.
- FDA Approval: ONGLYZA was first approved by the FDA in 2009 [7]. Subsequent approvals for combination therapies involving saxagliptin (e.g., with metformin) further expanded its market presence.
- EMA Approval: Received marketing authorization in the European Union in September 2009.
- Cardiovascular Safety Concerns: Early in its lifecycle, ONGLYZA, along with other DPP-4 inhibitors, was scrutinized for potential cardiovascular risks. Post-marketing studies, such as the SAVOR-TIMI 53 trial, investigated these concerns. While SAVOR-TIMI 53 did not demonstrate an increased risk of major adverse cardiovascular events in patients treated with saxagliptin compared to placebo, it did show a statistically significant increase in the risk of hospitalization for heart failure [8]. This finding has led to specific warnings and considerations in clinical practice and prescribing guidelines.
- Payer Restrictions: Reimbursement policies and formulary placement by health insurance providers and national health systems significantly impact ONGLYZA's market access. Factors such as cost-effectiveness, clinical trial data on cardiovascular outcomes, and guidelines from professional medical societies influence these decisions. The availability of generic alternatives further intensifies pressure on market access and pricing.
What is the Financial Outlook and Investment Implications?
The financial trajectory of ONGLYZA is characterized by a period of growth followed by a significant decline driven by patent expirations and intensified competition.
- Revenue Decline: As evidenced by the sales data, ONGLYZA's revenue has been in steady decline since its peak. The introduction of generic saxagliptin has significantly eroded its market share and pricing power.
- Impact on AstraZeneca: While ONGLYZA was a significant product, AstraZeneca's diversified portfolio means the decline of this single product has a manageable impact on the company's overall financial health. The company has strategically shifted its focus and investment towards newer, high-growth therapeutic areas and drug classes, including oncology, respiratory, and cardiovascular, renal & metabolism (CVRM) treatments with novel mechanisms of action.
- Generic Manufacturers: For generic pharmaceutical companies, ONGLYZA represents an opportunity to capture market share in the off-patent segment of the DPP-4 inhibitor market. Success in this segment depends on efficient manufacturing, effective distribution channels, and competitive pricing.
- Investment Implications: Investors in branded pharmaceuticals need to carefully assess the patent cliffs of existing drugs and the pipeline of new products. For ONGLYZA, the investment thesis has shifted from growth to value capture of the remaining branded market and for generic players, to market share acquisition. The focus for pharmaceutical companies is now on innovating beyond DPP-4 inhibitors to address unmet needs in diabetes management, particularly those with demonstrated cardiovascular and renal benefits.
Key Takeaways
- ONGLYZA (saxagliptin) is a DPP-4 inhibitor used to manage type 2 diabetes, originally developed by Bristol Myers Squibb and AstraZeneca.
- The global market for DPP-4 inhibitors has grown but is facing increasing competition and patent expirations.
- Key patents for ONGLYZA have expired in major markets, leading to the introduction of generic saxagliptin.
- ONGLYZA's net sales peaked around 2018-2019 and have since declined significantly due to generic competition and the rise of newer antidiabetic drug classes.
- Competition includes other DPP-4 inhibitors like Januvia and Tradjenta, as well as newer classes such as SGLT2 inhibitors and GLP-1 receptor agonists that offer cardiovascular and renal benefits.
- Regulatory considerations include post-marketing safety data, particularly regarding heart failure risk, and payer access restrictions based on cost-effectiveness and clinical value.
- The financial outlook for ONGLYZA is one of continued revenue decline for the branded product, while generic manufacturers can leverage patent expiries for market entry. AstraZeneca has strategically pivoted its investments to newer therapeutic areas.
Frequently Asked Questions
-
What is the primary reason for ONGLYZA's declining sales?
The primary reason for ONGLYZA's declining sales is the expiration of its key patents, which has allowed for the introduction of lower-cost generic versions of saxagliptin into the market. This has led to significant price erosion and loss of market share for the branded product.
-
Are there any significant safety concerns associated with ONGLYZA?
Yes, post-marketing studies, notably the SAVOR-TIMI 53 trial, indicated a statistically significant increase in the risk of hospitalization for heart failure in patients treated with saxagliptin compared to placebo. This has resulted in specific warnings on the drug's label and considerations for its use in patients with a history of heart failure.
-
How do SGLT2 inhibitors and GLP-1 receptor agonists impact ONGLYZA's market position?
SGLT2 inhibitors (e.g., Jardiance, Farxiga) and GLP-1 receptor agonists (e.g., Ozempic, Trulicity) represent a significant competitive threat because they offer not only glycemic control but also demonstrated cardiovascular and renal protective benefits. These additional benefits are increasingly prioritized by both physicians and patients in diabetes management, leading to a shift in prescribing away from older drug classes like DPP-4 inhibitors that lack comparable outcome data.
-
What is AstraZeneca's current strategic focus in the diabetes market?
AstraZeneca has strategically shifted its focus and investment towards newer, innovative treatments for diabetes and related conditions, particularly those demonstrating cardiovascular and renal benefits. The company is prioritizing research and development in areas with higher growth potential and unmet medical needs, moving beyond older drug classes with established generics.
-
What is the outlook for generic saxagliptin in the market?
The outlook for generic saxagliptin is one of increased market penetration and competition among generic manufacturers. As the branded product's exclusivity wanes, generic versions will likely capture a substantial portion of the market share due to their lower cost, providing an affordable treatment option for patients with type 2 diabetes.
Citations
[1] FDA. (2009, July 31). FDA Approves ONGLYZA (saxagliptin) Tablets. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fda-approves-onglyza-saxagliptin-tablets
[2] AstraZeneca. (2014, January 23). AstraZeneca takes full control of global diabetes alliance with Bristol-Myers Squibb. AstraZeneca. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-takes-full-control-of-global-diabetes-alliance-with-bristol-myers-squibb-23012014.html
[3] Grand View Research. (2023). DPP-4 Inhibitors Market Size, Share & Trends Analysis Report By Drug Type, By Disease Type, By Distribution Channel, By Region, And Segment Forecasts, 2023-2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/dpp-4-inhibitors-market (Note: Actual report access may require subscription)
[4] Allied Market Research. (2022). DPP-4 Inhibitors Market by Drug Type, Disease Type, and Distribution Channel: Opportunity Analysis and Industry Forecast, 2021-2031. Retrieved from https://www.alliedmarketresearch.com/dpp-4-inhibitors-market (Note: Actual report access may require subscription)
[5] AstraZeneca. (Various Years). Annual Reports. Retrieved from AstraZeneca Investor Relations website. (Specific report links are dynamic, direct access to investor relations section is recommended).
[6] AstraZeneca. (2024, February 8). Full-year results for the period ended 31 December 2023. AstraZeneca. Retrieved from https://www.astrazeneca.com/investor-relations/reports-and-events/results-and-presentations/full-year-results-for-the-period-ended-31-december-2023.html
[7] U.S. Food and Drug Administration. (2009, July 31). FDA Approves ONGLYZA (saxagliptin) Tablets. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fda-approves-onglyza-saxagliptin-tablets
[8] Scirica, B. M., Bhatt, D. L., Braunwald, E., Clement, A., Contreras, R., Dagogo-Jack, S., ... & Ting, R. (2013). Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 369(14), 1317-1324. doi: 10.1056/NEJMoa1307684
